German China

Breakthrough Technology Desktop Protein Printer Raises 42.5-Million-Dollars in Funding

Source: Press release

The biotech company Nuclera has raised 42.5-million-dollars at the first close of its Series B financing for its desktop protein printer - eProtein desktop bioprinter. The rapid protein prototyping and discovery platform helps one to print proteins in 24 hours and will initially screen and print proteins for research and drug discovery customers.

The eProtein desktop bioprinter has gained significant traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries.
The eProtein desktop bioprinter has gained significant traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries.
(Source: Nuclera)

Cambridge/UK – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, has recently announced that the first close of its Series B financing has raised 42.5 million dollars. The funds raised will be used to accelerate the development and commercialization of its eProtein desktop bioprinter.

Nuclera’s ground-breaking protein printing technology has attracted many new and existing institutional and strategic investors in this financing round including M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G. K. Goh.

The eProtein desktop bioprinter is a breakthrough rapid protein prototyping and discovery platform that enables protein printing in just 24 hours, significantly faster than existing methods of protein synthesis. The eProtein bioprinter is powered by the company’s eDrop digital microfluidic technology - a core enabling technology borne out of the company’s strategic partnership with E Ink. The technology has gained significant traction with customers in the pharmaceutical, biotech, agribiotech, and synthetic biology industries, which are already working with Nuclera to accelerate their innovation pipelines.

The eProtein desktop bioprinter will initially screen and print proteins for research and drug discovery customers, and the funding will also fast-track the company’s march towards developing an all-encompassing proteomics platform. This will provide Nuclera’s eProtein customers with an instrument that will unify protein expression and characterization. The all-in-one platform will increase scientific reproducibility, accelerate drug discovery, and contribute to the ever-expanding bio-economy.

“There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,” said Michael Chen, Co-founder and CEO of Nuclera. “Our eProtein desktop bioprinter makes it easy for scientists to access the proteins they need in a single day rather than the weeks, months, or even years it currently takes. The new financing and partners we are announcing today is a strong vote of confidence in our mission to increase the accessibility of the drug discovery and general bio-innovation process.”

Andrea Traversone, Managing Partner at Amadeus Capital Partners, added, “Nuclera’s eProtein platform unites the very fragmented workflow that currently exists in proteomics. Nuclera is bringing rapid prototyping—a concept that did not exist until now—to biotech, and by speeding up research and opening up completely new avenues of innovation, it will have a far-reaching impact in numerous markets.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:47977359)